Dr. Amit A. Johnsingh, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- State University of Ny Upstate Medical University (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 606
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: State University of Ny Upstate Medical University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
FL license ME98383 -
Internal Medicine Physician
FL license ME98383
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
- HCA Florida Brandon Hospital Brandon, FL
- HCA Florida South Shore Hospital Sun City Center, FL
- South Florida Baptist Hospital Plant City, FL
- Adventhealth Riverview Riverview, FL
Medical groups
- Florida Kidney Physicians LLC (169 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 606
- Services billed
- 3,214
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 633 | 347 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 340 | 56 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 210 | 123 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 159 | 96 |
| Dialysis services, per day, less than full month service (20 years or older) | 114 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 80 | 78 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 79 | 47 |
| Home dialysis services per month (20 years or older) | 69 | 16 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 59 | 26 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 54 | 50 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carvedilol Other prescribers in Temple Terrace, FL | 166 |
| Valsartan Other prescribers in Temple Terrace, FL | 115 |
| Furosemide Other prescribers in Temple Terrace, FL | 111 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Temple Terrace, FL | 106 |
| Amlodipine Besylate Other prescribers in Temple Terrace, FL | 105 |
| Jardiance (empagliflozin) Other prescribers in Temple Terrace, FL | 92 |
| Calcitriol Other prescribers in Temple Terrace, FL | 83 |
| Nifedipine Er (nifedipine) Other prescribers in Temple Terrace, FL | 76 |
| Losartan Potassium Other prescribers in Temple Terrace, FL | 65 |
| Allopurinol Other prescribers in Temple Terrace, FL | 55 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 40 payments worth $1,082 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $151 |
|---|---|
| Otsuka America Pharmaceutical, Inc. | $117 |
| Vantive US Healthcare LLC | $116 |
| Akebia Therapeutics Inc | $115 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $109 |
| Mallinckrodt Hospital Products Inc. | $100 |
| Amgen Inc. | $96.37 |
| Ardelyx, Inc. | $62.00 |
| Food and Beverage | $1,082 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $438,733 in research payments for these studies, mostly to the institutions running them.
- A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
AstraZeneca Pharmaceuticals LP - An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care W…
Novartis Pharmaceuticals Corporation - A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD
Boehringer Ingelheim Pharmaceuticals, Inc. - LUPKYNIS Registry Study
Aurinia Pharma U.S., Inc. - A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.